Scarica l'app Stockscreener
1.825
0.00%
0.025
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
What is Taysha Gene Therapies Inc (TSHA) Stock Return on Shareholders’ Capital? - Sete News
Taysha Gene Therapies’ (TSHA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities - Defense World
Understanding the Risks of Investing in Taysha Gene Therapies Inc (TSHA) - knoxdaily.com
Examining TSHA’s book value per share for the latest quarter - uspostnews.com
Taysha Gene Therapies Inc (NASDAQ: TSHA) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Geode Capital Management LLC Has $6.18 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Keeping an Eye on Taysha Gene Therapies Inc (TSHA) After Insider Trading Activity - knoxdaily.com
Taysha Gene Therapies Inc [TSHA] stock Initiated by BMO Capital Markets analyst, price target now $5 - dbtnews.com
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Anchoring Your Portfolio: Is TSHA Stock a Safe Harbor? - investchronicle.com
What is going on with Taysha Gene Therapies Inc? Sentiment Analysis - uspostnews.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co. - Defense World
Vanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity - Seeking Alpha
Wellington Management Group LLP Raises Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Commonwealth Equity Services LLC Purchases 31,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages - The AM Reporter
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors - The Manila Times
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Target Price from Brokerages - Defense World
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Expands Team: 822,000 Stock Options Awarded in Strategic Growth Move - Stock Titan
At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday - The AM Reporter
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
Alexandria Real Estate Equities, Inc. Elects Claire Aldridge, PhD, to Board of Directors - The Malaysian Reserve
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Yahoo Finance
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):